The Obesity Action Coalition (OAC) is pleased to share that Carmot Therapeutics, Inc. has joined OAC’s Chairman’s Council at the Bronze level! Thank you for committing to support and champion the OAC’s mission.

About Carmot Therapeutics, Inc. 

Carmot Therapeutics is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases, including obesity and diabetes. Carmot’s expertise in metabolic biology has enabled the development of a broad pipeline of therapeutics, including three clinical candidates: CT-388 (once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist), CT-868 (once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist) and CT-996 (once-daily oral, small molecule GLP-1 receptor agonist), and others in preclinical development. All of these are proprietary novel compounds, wholly-owned by Carmot, that have the potential to deliver an enhanced treatment response in people with metabolic diseases.

About the OAC Chairman’s Council

The OAC is honored that Carmot Therapeutics, Inc. has chosen to support our organization at the Bronze level through the Chairman’s Council as we strive to partner with industry leaders who share our mission of supporting and empowering individuals in their health journeys.

The OAC welcomes ANY individual, organization or company who wishes to join our highest level of OAC Membership and receive maximum benefits. Our Chairman’s Council is an excellent way to give back to the cause and play an integral role in making the world a better place for people with obesity. To learn more about the OAC’s Chairman’s Council, click here.